CAS 80295-53-0|C5, HUMAN
| Common Name | C5, HUMAN | ||
|---|---|---|---|
| CAS Number | 80295-53-0 | Molecular Weight | / |
| Density | / | Boiling Point | / |
| Molecular Formula | / | Melting Point | / |
| MSDS | USA | Flash Point | / |
Names
| Name | C5, HUMAN |
|---|
Chemical & Physical Properties
| Storage condition | −70°C |
|---|
Safety Information
| Hazard Codes | B |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles3
More Articles| Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350 , 552-559, (2004) Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface protei... | |
| Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3. Mini Rev. Med. Chem. 11 , 528-535, (2011) Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evide... | |
| The role of complement inhibition in PNH. Hillmen P. Hematology Am. Soc. Hematol. Educ. Program 2008(1) , 116-123, (2008) |
